Temozolomide (TMZ), an alkylating drug used for the treatment of gliomas, has to date not been exploited for its potential role as a radionuclide-imaging probe. This study reports the radiosynthesis of [99mTc]Tc-TMZ and evaluates its specificity for glioma using C6 cell lines.
Methods:
TMZ was labeled with 99mTc, optimized for reaction conditions and radiochemical purity. Physicochemical characterization was performed by evaluating plasma protein binding, stability in saline and serum, and partition coefficient. Furthermore, the cellular uptake and internalization mechanism of [99mTc]Tc-TMZ were determined in C6 cells. The toxicity of the radiotracer was determined by performing the MTT and hemolysis assays.
Results:
The radiocomplex was synthesized with >90% radiochemical purity. The radiocomplex exhibited neutral charge, high lipophilicity, low plasma protein binding, and physiological stability in in vitro conditions. Cell binding studies exhibited [99mTc]Tc-TMZ specificity for C6 cells in a concentration- and time-dependent manner, with maximum uptake at 12.5 μg and passive diffusion as the primary mode of transport. Toxicity studies revealed more than 50% damage to the cells with minimal hemolytic activity at 50 μg concentration of TMZ in radiocomplex.
Conclusions:
These preliminary findings suggest the specificity of [99mTc]Tc-TMZ for C6 cells and warrant further exploration as a SPECT radiotracer for glioma imaging.
HanifF, MuzaffarK, PerveenK, et al.Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev, 2017; 18(1):3–9. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5563115/
2.
BeckerAP, SellsBE, Jaharul HaqueS, et al.Tumor heterogeneity in glioblastomas: From light microscopy to molecular pathology. Cancers (Basel), 2021; 13(4):761. Available from: https://www.mdpi.com/2072-6694/13/4/761/htm
3.
QaziMA, VoraP, VenugopalC, et al.Intratumoral heterogeneity: Pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol, 2017; 28(7):1448–1456. Available from: https://pubmed.ncbi.nlm.nih.gov/28407030/
HeissWD. PET bei gliomen: Eine übersicht der aktuellen literatur. Nuklearmedizin, 2014; 53(4):163–171; quiz N32. Available from: https://pubmed.ncbi.nlm.nih.gov/24853278/
WernerJM, LohmannP, FinkGR, et al.Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. Mol, 2020; 25(6):1471. Available from: https://www.mdpi.com/1420-3049/25/6/1471/htm
HaratM, BlokM, MiechowiczI, et al.Safety and Efficacy of Irradiation Boost Based on 18F-FET-PET in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res, 2022; 28(14):3011–3020. Available from: https://pubmed.ncbi.nlm.nih.gov/35552391/
10.
LaackNN, PafundiD, AndersonSK, et al.Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. Int J Radiat Oncol Biol Phys, 2021; 110(5):1383–1395. Available from: https://pubmed.ncbi.nlm.nih.gov/33771703/
11.
BergerM, GouldMK, BarnettPG. The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. AJR Am J Roentgenol, 2003; 181(2):359–365. Available from: https://pubmed.ncbi.nlm.nih.gov/12876011/
12.
O’ReillySM, NewlandsES, BramptonM, et al.Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer [Internet], 1993; 29(7):940–942. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0959804905801984
13.
StuppR, HegiME, MasonWP, et al.; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009; 10(5):459–466. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1470204509700257
14.
TachatumvitoonK, PreuksarattanawutC, TippayamontriT, et al.Tc-99m labeled PSMA-617 as a potential SPECT radiotracer for prostate cancer diagnostics: Complexation optimization and its in vitro/vivo evaluation. Bioorganic Med Chem [Internet], 2025; 118. Available from: https://pubmed.ncbi.nlm.nih.gov/39754852/
15.
HeeschA, MaurerJ, StickelerE, et al.Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target. Cells, 2020; 9(10):2334. Available from: https://www.mdpi.com/2073-4409/9/10/2334/htm
StevensMF, HickmanJA, StoneR, et al.Antitumor Imidazotetrazines. 1. Synthesis and Chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,l-d]-l,2,3,5-tetrazin-4(3H)-one, A Novel Broad-spectrum Antitumor Agent. J Med Chem, 1984; 27(2):196–201; doi: 10.1021/jm00368a016
18.
Michigan university of. I-TASSER server for protein structure and function prediction [Internet]. 2023. Available from: https://zhanggroup.org/I-TASSER/
19.
ZhangJ, Stevens MFG, D, BradshawT. Temozolomide: Mechanisms of action, repair and resistance. CMP, 2012; 5(1):102–114. Available from: https://pubmed.ncbi.nlm.nih.gov/22122467/
20.
StuppR, MasonWP, van den BentMJ, et al.; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med, 2005; 352(10):987–996; doi: 10.1056/NEJMoa043330
ZolleU. Technetium-99m pharmaceuticals: Preparation and quality control in nuclear medicine. Technetium-99m Pharm Prep Qual Control Nucl Med, 2007:1–345.
23.
JanG, BhatS, ChauhanM, et al.Target Specific Uptake of a Newly Synthesized Radiolabeled 5α-Reductase Inhibitor “Tc-99m-17-Oxo-17a-Aza-D-Homo-5-Androsten-3β-yl Phenoxyacetate (Tc-99m-17a-Aza Steroid)” in Rat Prostatic Neoplastic Lesions. Indian J Nucl Med, 2022; 37(2):133–141. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9380797/
24.
KhanNUH, NaqviSAR, RoohiS, et al.Technetium-99m radiolabeling and biological study of epirubicin for in vivo imaging of multi-drug-resistant Staphylococcus aureus infections via single photon emission computed tomography. Chem Biol Drug Des, 2019; 93(2):154–162; doi: 10.1111/cbdd.13393
25.
LeoA, HanschC, JowYC. Dependence of hydrophobicity of apolar molecules on their molecular volume. J Med Chem, 1976; 19(5):611–615; doi: 10.1021/jm00227a007
26.
PratiwiR, MahmudahDIA, SaptariniNM, et al.Comparison of Partition Coefficient (LOG P) of drugs: Computational and experimental data study. Int J Appl Pharm [Internet], 2023; 15(Special Issue 2):155–162. Available from: https://journals.innovareacademics.in/index.php/ijap/article/view/50169
27.
NaqviSAR, MatzowT, FinucaneC, et al.Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo. Cancer Biother Radiopharm, 2010; 25(1):89–95. Available from: https://pubmed.ncbi.nlm.nih.gov/20187801/
28.
Raza NaqviSA, SosabowskiJK, Ahamad NagraS, et al.Radiopeptide internalisation and externalisation assays: Cell viability and radioligand integrity. Appl Radiat Isot, 2011; 69(1):68–74. Available from: https://pubmed.ncbi.nlm.nih.gov/20880713/
29.
MosmannT. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 1983; 65(1–2):55–63. Available from: https://pubmed.ncbi.nlm.nih.gov/6606682/
30.
TanAC, AshleyDM, LópezGY, et al.Management of glioblastoma: State of the art and future directions. CA Cancer J Clin, 2020; 70(4):299–312; doi: 10.3322/caac.21613
31.
JezierzańskiM, NafalskaN, StopyraM, et al.Temozolomide (TMZ) in the treatment of glioblastoma multiforme—A literature review and clinical outcomes. Curr Oncol, 2024; 31(7):3994–4002. Available from: https://www.mdpi.com/1718-7729/31/7/296/htm
32.
AlexiouGA, TsiourisS, KyritsisAP, et al.The Value of 99mTc-Tetrofosmin Brain SPECT in Predicting Survival in Patients with Glioblastoma Multiforme. J Nucl Med, 2010; 51(12):1923–1926. Available from: https://jnm.snmjournals.org/content/51/12/1923
SaleemSM, JabbarT, ImranMB, et al.Radiosynthesis and preclinical evaluation of [99mTc]Tc-Tigecycline radiopharmaceutical to diagnose bacterial infections. Pharmaceuticals (Basel), 2024; 17(10):1283. Available from: https://www.mdpi.com/1424-8247/17/10/1283/htm
ShimizuY, AndoM, IikuniS, et al.Development of a hydroxamamide-based bifunctional chelating agent to prepare technetium-99m-labeled bivalent ligand probes. Sci Rep, 2021; 11(1):18714. Available from: https://www.nature.com/articles/s41598-021-98235-x
37.
NaqviSAR, JabbarT, AlharbiMA, et al.Radiosynthesis, quality control, biodistribution, and infection-imaging study of a new 99mTc-labeled ertapenem radiopharmaceutical. Front Chem, 2022; 10:1020387. Available from: https://pubmed.ncbi.nlm.nih.gov/36426099/
38.
YaghoobiF, Rashidiyan HarsiniP, Karimi ShervedaniR, et al.The physicochemical behavior of temozolomide stabilized on folic acid−targeted−gold−thiol modified surface via covalent conjugation towards cancer cells. Colloids Surfaces A Physicochem Eng Asp [Internet], 2023; 677:132286. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0927775723013705
39.
SchümichenC, KochK, KrausA, et al.Binding of technetium-99m to plasma proteins: Influence on the distribution of Tc-99m phosphate agents. J Nucl Med, 1980; 21(11):1080–1085. Available from: https://pubmed.ncbi.nlm.nih.gov/7431108/
LevinVA, PradosMR, WaraWM, et al.Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys, 1995; 32(1):75–83. Available from: https://www.sciencedirect.com/science/article/abs/pii/0360301694004887
42.
JanjuaTI, CaoY, Ahmed-CoxA, et al.Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. J Control Release, 2023; 357:161–174. Available from: https://pubmed.ncbi.nlm.nih.gov/36965857/
43.
KarveAS, DesaiJM, GadgilSN, et al.A review of approaches to potentiate the activity of temozolomide against glioblastoma to overcome resistance. Int J Mol Sci, 2024; 25(6):3217. Available from: https://www.mdpi.com/1422-0067/25/6/3217/htm
44.
StéphanouA, BallestaA. pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study. Pharmacol Res Perspect, 2019; 7(1):e00454; doi: 10.1002/prp2.454
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
